<DOC>
	<DOCNO>NCT00567567</DOCNO>
	<brief_summary>This randomized phase III trial compare two different high-dose myeloablative chemotherapy regimen follow autologous stem cell transplant consolidation treatment young patient high-risk neuroblastoma . All patient receive 6 cycle initial multi-agent chemotherapy induction regimen . Peripheral blood stem cell collect 2nd cycle chemotherapy . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Patients underwent resection primary tumor mass 5 cycle chemotherapy . Those patient without progressive disease completion induction therapy sufficient stem cell collect adequate organ function eligible proceed consolidation therapy . Those patient meet consolidation eligibility randomize either single myeloablative regimen 2 myeloablative regimen deliver tandem follow re-infusion autologous stem cell . Patients receive radiation therapy recovery assign myeloablative therapy . It yet know regimen high-dose chemotherapy effective patient high-risk neuroblastoma undergoing peripheral blood stem cell transplant .</brief_summary>
	<brief_title>Comparing Two Different Myeloablation Therapies Treating Young Patients Who Are Undergoing Stem Cell Transplant High-Risk Neuroblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To improve 3-year event-free survival ( EFS ) rate high-risk neuroblastoma patient treatment tandem consolidation thiotepa/cyclophosphamide follow carboplatin/etoposide/melphalan ( CEM ) compare single CEM consolidation . II . To improve rate end-induction complete response good partial response , compare historical control , use topotecan-containing induction regimen . III . To improve 3-year local control rate , compare historical control , increase local dose radiation residual primary tumor patient less gross total resection . SECONDARY OBJECTIVES : I . To evaluate pharmacogenetic relationship cyclophosphamide metabolize enzyme ( i.e. , cytochrome p 450 2B6 [ CYP2B6 ] , CYP2C9 , glutathione S-transferase alpha 1 [ GSTA1 ] genotype ) toxicity response follow dose-intensive cyclophosphamide topotecan induction chemotherapy . II . To determine resection completeness predictive local control rate EFS rate patient high-risk neuroblastoma . III . To prospectively describe complication relate effort local control ( i.e. , surgery radiotherapy ) patient high-risk neuroblastoma . IV . To describe neurologic outcome patient paraspinal primary neuroblastoma tumor . V. To determine variability isotretinoin pharmacokinetics ( PKs ) relationship pharmacogenomic parameter . VI . To determine isotretinoin PK level predictive EFS rate associate systemic toxicity follow isotretinoin . VII . To determine pharmacogenomic variation predictive EFS rate associate systemic toxicity follow isotretinoin . VIII . To evaluate total topotecan PKs correlate patient specific data use ongoing topotecan population PK analysis . IX . To evaluate presence function T cell capable recognize neuroblastoma assess follow ; T cell recognize neuroblastoma antigen , survivin , circulate diagnosis ; T cell expand use autologous antigen present cell ( APCs ) ; T cell kill neuroblastoma cell detect functional assay ; presence activity anti-neuroblastoma immunity decrease stem cell transplantation . X . To characterize recovery T-cell number myeloablative consolidation hematopoietic stem cell transplantation ( HSCT ) ass impact tandem myeloablative consolidation T-cell recovery . XI . To characterize minimal residual disease burden use reverse transcriptase-polymerase chain reaction ( RT-PCR ) evaluation panel neuroblastoma specific transcript patient bone marrow peripheral blood follow induction chemotherapy single versus tandem myeloablative chemotherapy evaluate impact EFS . XII . To evaluate EFS overall survival patient nonrandomly assign treatment single myeloablative transplant ( Arm A ) . OUTLINE : INDUCTION CHEMOTHERAPY : COURSES 1 AND 2 : Patients receive cyclophosphamide IV 30 minute topotecan hydrochloride IV 30 minute day 1-5 filgrastim ( G-CSF ) subcutaneously ( SC ) IV begin day 6 continue blood count recover . Treatment repeat every 21 day 2 course . Patients undergo peripheral blood stem cell ( PBSC ) mobilization harvest course 2 . COURSES 3 AND 5 : Patients receive cisplatin IV 1 hour day 1-4 , etoposide IV 1 hour day 1-3 , G-CSF SC IV begin day 5 continue blood count recover . Treatment repeat every 21 day 2 course . Patients undergo surgical resection soft tissue disease course 5 ( course 6 medically necessary ) . COURSES 4 AND 6 : Patients receive cyclophosphamide IV 6 hour day 1-2 , doxorubicin hydrochloride IV 24 hour day 1-3 , vincristine IV day 1-3 , G-CSF SC IV begin day 5 continue blood count recover . Treatment repeat every 21 day 2 course . At end induction , patient adequate organ function peripheral blood stem cell collection eligible undergo randomize assignment Consolidation therapy . Randomization stratify initial stage disease , MYCN status , response induction chemotherapy ( complete response/very good partial response vs partial response v mixed response/no response ) . Patients randomize 1 2 arm ( single myeloablative regimen autologous stem cell support , arm A tandem ( 2 ) myeloablative regimen follow autologous stem cell support , arm B ) . Patients 12-18 month old ( i.e. , 365-547 day ) stage IV , MYCN nonamplified tumor unfavorable histopathology diploid DNA content indeterminant histology ploidy AND patient great 547 day age stage III , MYCN nonamplified tumor AND unfavorable histopathology indeterminant histology nonrandomly assign Arm A . Consolidation chemotherapy recommend begin later 8 week start induction course 6 . CONSOLIDATION THERAPY : ARM A ( single myeloablative consolidation ) : Patients receive melphalan IV 15-30 minute day -7 -5 , etoposide IV 24 hour carboplatin IV 24 hour day -7 -4 , G-CSF SC IV begin day 0 continue blood count recover . Patients undergo autologous peripheral blood stem cell transplant ( PBSCT ) day 0 . ARM B ( tandem myeloablative consolidation ) : Patients receive thiotepa IV 2 hour day -7 -5 , cyclophosphamide IV 1 hour day -5 -2 , G-CSF SC IV begin day 0 continue blood count recover . Following clinical recovery initial myeloablative therapy , patient also receive melphalan , etoposide , carboplatin Arm A reduce dosage . Patients undergo autologous PBSCT day 0 . RADIOTHERAPY : Patients undergo external beam radiation therapy ( EBRT ) primary site disease well MIBG-avid site see pre-transplantation ( i.e. , end- induction ) evaluation sooner day 28 recommend 42 day post-transplant . An additional boost radiotherapy administer residual tumor primary site . MAINTENANCE THERAPY : Patients encourage enroll onto Children 's Oncology Group ( COG ) -ANBL0032 follow assessment tumor response completion consolidation phase radiotherapy . Beginning day 60 post-transplantation patient receive oral isotretinoin twice daily day 1-14 . Treatment repeat every 28 day 6 month absence disease progression unacceptable toxicity . Patients undergo blood tissue sample collection periodically follow analysis ; correlation peak serum concentration level cyclophosphamide metabolites existence polymorphisms gene involve cyclophosphamide metabolism , event-free survival , toxicity rate ; pharmacogenomics uridine diphosphate ( UDP ) glucuronosyltransferase 1 family , polypeptide A1 ( UGT1A1 ) , UGT2B7 , CYP2C8 CYP3A7 alleles ; topotecan systemic clearance ; survivin-specific cytotoxic T-lymphocytes ( CTLs ) detect use peptide/major histocompatibility complex ( MHC ) tetramers human leukocyte antigen ( HLA ) -A2+ patient ; interferon ( IFN ) -gamma production enzyme-linked immunospot ( ELISPOT ) assay APCs load tumor ribonucleic acid ( RNA ) , survivin RNA , control RNA ; response APC-stimulated CTL response neuroblastoma cell ; rate T cell recovery ; proportion patient neuroblastoma detect bone marrow peripheral blood use RT-PCR immunohistochemistry ( IHC ) . After completion study treatment , patient follow periodically 5 year annually 5 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Nitrogen Mustard Compounds</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<criteria>Diagnosis neuroblastoma ganglioneuroblastoma histology evidence presence clump tumor cell bone marrow elevate catecholamine metabolite urine meeting follow criterion : Patients newly diagnose neuroblastoma International Neuroblastoma Staging System ( INSS ) stage 4 disease eligible following : MYCN amplification ( i.e. , great fourfold increase MYCN signal compare reference signal ) , regardless age additional biologic feature Age &gt; 18 month ( i.e. , &gt; 547 day ) regardless biologic feature Age 1218 month ( i.e. , 365547 day ) none follow three favorable biologic feature ( i.e. , nonamplified MYCN , favorable pathology , deoxyribonucleic acid [ DNA ] index &gt; 1 ) Patients newly diagnose neuroblastoma INSS stage 3 eligible following : MYCN amplification ( i.e. , great fourfold increase MYCN signal compare reference signal ) , regardless age additional biologic feature Age &gt; 18 month ( i.e. , &gt; 547 day ) unfavorable pathology , regardless MYCN status Patients newly diagnose INSS stage 2a 2b MYCN amplification ( i.e. , great fourfold increase MYCN signal compare reference signal ) , regardless age additional biologic feature Patients newly diagnose INSS stage 4 MYCN amplification ( i.e. , great fourfold increase MYCN signal compare reference signal ) , regardless additional biologic feature Patients &gt; = 365 day initially diagnose INSS stage 1 , 2 , 4S progress stage 4 without interval chemotherapy Must enrol COGANBL00B1 Creatinine clearance radioisotope glomerular filtration rate ≥ 70mL/min OR serum creatinine base age/gender follow : 1 month &lt; 6 month : 0.4 mg/dL 6 month &lt; 1 year : 0.5 mg/dL 1 &lt; 2 year : 0.6 mg/dL 2 &lt; 6 year : 0.8 mg/dL 6 &lt; 10 year : 1 mg/dL 10 &lt; 13 year : 1.2 mg/dL 10 &lt; 16 year : 1.5 mg/dL ( male ) , 1.4 mg/dL ( female ) &gt; = 16 year : 1.7 mg/dL ( male ) , 1.4 mg/dL ( female ) Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) age Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 10 time ULN age Not pregnant nursing Negative pregnancy test Shortening fraction &gt; = 27 % echocardiogram ( ECHO ) OR leave ventricular ejection fraction ( LVEF ) &gt; = 50 % radionuclide angiogram No know contraindication ( e.g. , size , weight physical condition ) peripheral blood stem cell collection No prior systemic therapy except localized emergency radiation sit lifethreatening functionthreatening disease No one course chemotherapy per low intermediaterisk neuroblastoma therapy prior determination MYCN amplification histology</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>